This non-profit biopharmaceutical research consortium supports and facilitates multi-stakeholder innovation to accelerate the transformation of cutting-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs, while generating significant benefits for the Canadian economy.
An Innovative Funding Model
The unique funding model of the NPO, founded in 2008, helps bridge the gap between discovery and commercial development at the early stage.
Thus, the financial support of CQDM and its partners intervenes at a critical phase of innovation within life sciences SMEs to:
• pool costs;
• lessen risks;
• reduce drug development time.
Through the industrial collaborative research funded by CQDM, each of the stakeholders – researchers, academic laboratories, SMEs and pharmaceutical companies – will draw benefits.
Innovation Through Collaboration: From the Laboratory to Industry
The public-private collaborative research model leads to multidisciplinary and transdisciplinary collaborations that foster the emergence of highly competitive innovations. On the one hand, companies have easier access to academic expertise and cutting-edge technologies, while on the other hand, researchers can add value to their discoveries by facilitating technology transfer. Furthermore, by joining forces, both the academic and industrial sectors contribute to the next generation of biopharmaceutical researchers.
CQDM supports biotechnology companies in several ways:
• Provides a showcase for Québec innovations to large multinational pharmaceutical companies;
• Creates opportunities for exchange and networking between academic and industrial researchers and promotes multidisciplinary
and public/private collaborations with high added value;
• Helps Québec companies innovate by financing innovative and highly competitive industrial R&D that satisfies unmet medical needs.
